C-PQV4mitochondrial therapeutics, VDAC1 modulation, precision biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Support precision-medicine development of mitochondrial therapeutics for neurodegenerative diseases.
Precision biomarkers associated with mitochondrial therapeutics and VDAC1 modulation.
Described in the supplied site analysis as part of X-tosis's primary approach; no specific assay, validation study, or clinical milestone was provided.
Develop VDAC1-modulating mitochondrial therapeutics intended to restore mitochondrial function, reduce inflammation, and prevent neuronal death in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, and related conditions.
Small-molecule VDAC1 modulation / VDAC1 oligomerization inhibition targeting mitochondria-linked programmed cell death pathways.
Listed as the company's pipeline program; related 2026 publication reported VDAC1 inhibitors VBIT-4 and VBIT-12 protected against apoptosis, pyroptosis, ferroptosis, mitochondrial dysfunction, inflammatory signaling, and disease-associated pathology in mouse models.
Related preclinical evidence reported reduced reactive oxygen species, intracellular calcium, inflammasome activation, and pathology in Alzheimer's disease and inflammatory bowel disease mouse models using VBIT-4 and VBIT-12.